Sat, Aug 23, 2014, 9:41 AM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Sarepta Therapeutics, Inc. Message Board

  • encore7 encore7 Jun 14, 2013 10:01 AM Flag

    Why no analyst recommendation to the shorts??

    Don't they deserve some sage advice too? The following would be appropriate now IMHO:

    Encore Investment Analytics Inc makes cautious comments on Sarepta short position. With 40% of stock now short, short sellers risk major losses on any further positive indications regarding FDA AA request. Expected inclusion of SRPT in Russell 2000 index provides further major risk to short view. Recommend reducing short position ahead of any positive catalysts.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
21.71+0.22(+1.02%)Aug 22 3:59 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.